Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence.
We administered intracavernous injections of 20 micrograms. prostaglandin E1 to 135 patients with impotence, and evaluated the effects and side effects. Among 135 patients who underwent intracavernous injection of prostaglandin E1 complete erection was observed in 83 (62 per cent), while incomplete erection was noted in 33 (24 per cent). In both groups the erection was sufficient for sexual intercourse. Tumescence without rigidity was noted in 12 patients and no response was obtained in 7. Poor response was seen frequently in patients with disorders of the vascular system and/or damage to the cavernous body of the penis. Priapism after the injection was not observed. Moreover, we never observed any other severe side effects. Intracavernous injection of prostaglandin E1 could be applicable to the therapy of impotence, especially that due to neurogenic disturbance. Since prostaglandin E1 acts quickly and loses its validity rapidly it is considered to be a more suitable agent than other vasoactive drugs.
Ishii
N
N
Department of Urology, University of Yamagata, Japan.
Watanabe
H
H
Irisawa
C
C
Kikuchi
Y
Y
Kubota
Y
Y
Kawamura
S
S
Suzuki
K
K
Chiba
R
R
Tokiwa
M
M
Shirai
M
M
D000328:Adult; D000368:Aged; D000527:Alprostadil / Q000008:administration & dosage* / Q000627:therapeutic use; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010410:Penile Erection / Q000187:drug effects*
D000527:Alprostadil